Goldman Sachs Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Raises Target Price to $27
Goldman Sachs analyst Richard Law CFA maintains $Olema Pharmaceuticals(OLMA.US)$ with a buy rating, and adjusts the target price from $24 to $27.According to TipRanks data, the analyst has a success
Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth
Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference
JP Morgan Maintains Overweight on Olema Pharmaceuticals, Lowers Price Target to $31
Express News | Olema Pharmaceuticals Inc : JP Morgan Cuts Target Price to $31 From $33
Olema Pharmaceuticals Price Target Maintained With a $30.00/Share by HC Wainwright & Co.
Oppenheimer Reiterates Outperform on Olema Pharmaceuticals, Maintains $30 Price Target
Olema Pharmaceuticals Analyst Ratings
Buy Rating Reaffirmed for Olema Pharmaceuticals Amid Promising Breast Cancer Treatment Advances and Strong Financials
Buy Rating Affirmed for Olema Pharmaceuticals Amidst Promising Clinical Developments and Strategic Collaborations
Olema Pharmaceuticals GAAP EPS of -$0.54 Beats by $0.01
Olema Pharmaceuticals | 10-Q: Q2 2024 Earnings Report
Express News | Olema Oncology Q2 Basic EPS USD -0.54 Vs. IBES Estimate USD -0.55
Express News | Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Express News | Olema Oncology Q2 Income From Operations USD -33.53 Million
Express News | Olema Oncology Q2 Operating Expenses USD 33.53 Million
Express News | Olema Oncology Q2 Net Income USD -30.382 Million
Insider Sellers Might Regret Selling Olema Pharmaceuticals Shares at a Lower Price Than Current Market Value
Olema Pharmaceuticals(OLMA.US) Director Sells US$215.4K in Common Stock
$Olema Pharmaceuticals(OLMA.US)$ Director Harmon Cyrus sold 20,000 shares of common stock on Jun 28, 2024 at an average price of $10.77 for a total value of $215.4K.Source: Announcement What is statem
Express News | Olema Pharmaceuticals: Amendment Increases Aggregate Principal Amount of Loan Facility to up to $100 Mln